These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN. Rev Esp Med Nucl Imagen Mol; 2014 Sep 01; 33(1):22-7. PubMed ID: 23948509 [Abstract] [Full Text] [Related]
14. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A, Kalinyak JE, McDougall IR. Clin Nucl Med; 2007 Sep 01; 32(9):690-5. PubMed ID: 17710020 [Abstract] [Full Text] [Related]
16. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, Roedel R, Strunk H, Bieber T, Biersack HJ, Tüting T. J Clin Oncol; 2006 Mar 01; 24(7):1178-87. PubMed ID: 16505438 [Abstract] [Full Text] [Related]
20. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Wong TZ, Jones EL, Coleman RE. Mol Imaging Biol; 2004 Mar 01; 6(1):55-62. PubMed ID: 15018829 [Abstract] [Full Text] [Related] Page: [Next] [New Search]